TransCode Therapeutics receives Nasdaq deficiency notice for low stockholders' equity

Transcode Therapeutics, Inc.

Stockholders' equity reported at $1.25M as of March 31, 2026, below Nasdaq's $2.5M minimum.
Company has 45 days (until July 3, 2026) to submit a plan to regain compliance.
Plan hinges on stockholder approval to convert Series A Preferred Stock into common equity.
If plan is rejected or compliance not regained within extension, Nasdaq may delist RNAZ.
Failure to obtain approval by Dec 31, 2026 could trigger redemption of Series A Preferred at fair value.

item 3.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001104659-26-065959
form_type: 8-K/A
ticker: RNAZ
cik: 0001829635
company_name: Transcode Therapeutics, Inc.
filed_at: 2026-05-26T10:43:50+00:00
discovered_at: 2026-05-26T10:45:00.320300+00:00
generated_at: 2026-05-26T10:45:05.007062+00:00
sec_items: ["3.01"]
event_type: regulatory
sentiment: negative
materiality_score: 0.8
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001104659-26-065959
json_url: https://secwatch.observer/filing/0001104659-26-065959.json
markdown_url: https://secwatch.observer/filing/0001104659-26-065959.md
text_url: https://secwatch.observer/filing/0001104659-26-065959.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1829635/000110465926065959/0001104659-26-065959-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1829635/000110465926065959/tm2615597d1_8ka.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0001104659-26-065959

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.